US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

24.17

+1.315.73%

Post-market: 23.83-0.3400-1.41%19:30 EDT

Volume:934.81K

Turnover:22.12M

Market Cap:3.12B

PE:-6.36

High:24.70

Open:22.98

Low:22.21

Close:22.86

52wk High:31.35

52wk Low:3.76

Shares:129.00M

Float Shares:109.67M

Volume Ratio:1.01

T/O Rate:0.85%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.8005

EPS(LYR):-2.8616

ROE:-93.65%

ROA:-45.34%

PB:6.90

PE(LYR):-8.45

Loading ...

Overview Company News Filings

Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50

THOMSON REUTERS

Alumis price target raised to $55 from $50 at Oppenheimer

Alumis Is Maintained at Buy by HC Wainwright & Co.

Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission

Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24

Alumis: New Data From Its Phase 3 Onward1 & Onward2 Clinical Trials Evaluating Envudeucitinib

THOMSON REUTERS

Alumis: Envudeucitinib Showed Favorable Safety & Tolerability Profile Consistent With Phase 2 Program, No New Safety Signals Observed

THOMSON REUTERS

Alumis: Envudeucitinib Showed Robust Skin‑Clearance, Achieving High Thresholds of Clinical Responses From Week 16 to Week 24 in Both Trials

THOMSON REUTERS

Alumis: Continues to Evaluate Long-Term Efficacy & Safety of Envudeucitinib in Onward3 Long-Term Extension Trial

THOMSON REUTERS

The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity Plans - Learn Why

Simply Wall St.

Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative

Simply Wall St.

Alumis Is Maintained at Overweight by Morgan Stanley

Alumis Is Maintained at Buy by Chardan Capital

Alumis price target raised to $38 from $33 at Morgan Stanley

Calendar of U.S. Earnings Expected in the Week Ahead

U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedEx

Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/ALMS/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALMS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":24.17,"timestamp":1787342400000,"preClose":22.86,"halted":0,"volume":934814,"hourTrading":{"tag":"盘后","latestPrice":23.83,"preClose":24.17,"latestTime":"19:30 EDT","volume":15863,"amount":381577.5044,"timestamp":1787355007243,"change":-0.34,"changeRate":-0.014067,"amplitude":0.059164},"delay":0,"changeRate":0.05730533683289599,"floatShares":109674768,"shares":129000000,"eps":-3.800544,"marketStatus":"Market Closed","change":1.31,"latestTime":"08-21 16:00:00 EDT","open":22.98,"high":24.698,"low":22.21,"amount":22124289.6787,"amplitude":0.108836,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":22.86,"preHourTrading":{"tag":"盘前","latestPrice":22.96,"preClose":22.86,"latestTime":"09:29 EDT","volume":499,"amount":11565.89685,"timestamp":1787318999999,"change":0.1,"changeRate":0.004374,"amplitude":0.064742},"postHourTrading":{"tag":"盘后","latestPrice":23.83,"preClose":24.17,"latestTime":"19:30 EDT","volume":15863,"amount":381577.5044,"timestamp":1787355007243,"change":-0.34,"changeRate":-0.014067,"amplitude":0.059164},"volumeRatio":1.013795348835072,"optionData":{"bulkOrders":[{"symbol":"ALMS","call":true,"expireDate":1789704000000,"strike":"35.0","timestamp":1787337187709,"price":2.85,"volume":1680,"amount":478800,"type":"+"}]},"impliedVol":1.9712,"impliedVolPercentile":0.9203},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALMS\",,,,,undefined,":{"symbol":"ALMS","floatShares":109674768,"roa":"-45.34%","roe":"-93.65%","lyrEps":-2.861649,"volumeRatio":1.013795348835072,"shares":129000000,"dividePrice":0,"high":24.698,"amplitude":0.108836,"preClose":22.86,"low":22.21,"week52Low":3.76,"pbRate":"6.90","psRate":"421.46","week52High":31.35,"institutionHeld":0,"latestPrice":24.17,"eps":-3.800544,"divideRate":0,"volume":934814,"delay":0,"ttmEps":-3.800544,"open":22.98,"prevYearClose":9.76,"prevWeekClose":25.31,"prevMonthClose":28.25,"prevQuarterClose":28.14,"fiveDayClose":25.31,"twentyDayClose":28,"sixtyDayClose":21.33},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALMS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ALMS","fiscalQuarterEnding":"2026/06","expectedEps":-0.7,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.78},{"market":"US","date":"2026-05-14","symbol":"ALMS","fiscalQuarterEnding":"2026/03","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2026-03-19","symbol":"ALMS","fiscalQuarterEnding":"2025/12","expectedEps":-0.97,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":-0.95},{"market":"US","date":"2025-11-13","symbol":"ALMS","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-1.06},{"market":"US","date":"2025-08-13","symbol":"ALMS","fiscalQuarterEnding":"2025/06","expectedEps":-1.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-1.17}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALMS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALMS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.3,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":10,"updateTime":1778904000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ALMS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ALMS","date":"2026-08-21","current":-6.359616,"percent":0.28757,"low":-16.271116,"twenty":-12.30227,"median":-3.108556,"eighty":-1.162092,"high":-0.443678,"avg":-5.273389,"sd":5.065123,"marketCap":2958889563},"quantilePoints":[{"date":"2024-06-28","current":-4.084559,"twenty":-4.913756,"median":-4.913756,"eighty":-4.416238,"marketCap":689534895},{"date":"2024-07-05","current":-3.516406,"twenty":-4.747917,"median":-3.851156,"eighty":-3.59564,"marketCap":593622147},{"date":"2024-07-12","current":-3.405847,"twenty":-4.063676,"median":-3.825051,"eighty":-3.58397,"marketCap":574958044},{"date":"2024-07-19","current":-4.023985,"twenty":-4.026561,"median":-3.851156,"eighty":-3.52869,"marketCap":679309112},{"date":"2024-07-26","current":-4.023985,"twenty":-4.117224,"median":-3.947896,"eighty":-3.58397,"marketCap":679309112},{"date":"2024-08-02","current":-4.178507,"twenty":-4.123137,"median":-3.980142,"eighty":-3.620209,"marketCap":705394582},{"date":"2024-08-09","current":-3.850149,"twenty":-4.108328,"median":-3.938677,"eighty":-3.693301,"marketCap":649962958},{"date":"2024-08-16","current":-3.683794,"twenty":-4.085032,"median":-3.914533,"eighty":-3.659692,"marketCap":696362265},{"date":"2024-08-23","current":-3.672282,"twenty":-4.078883,"median":-3.855481,"eighty":-3.667968,"marketCap":694186133},{"date":"2024-08-30","current":-3.655014,"twenty":-4.050383,"median":-3.84693,"eighty":-3.659692,"marketCap":690921935},{"date":"2024-09-06","current":-3.442045,"twenty":-4.027205,"median":-3.798947,"eighty":-3.608967,"marketCap":650663491},{"date":"2024-09-13","current":-3.33556,"twenty":-4.023985,"median":-3.741353,"eighty":-3.511116,"marketCap":630534270},{"date":"2024-09-20","current":-3.301025,"twenty":-4.023985,"median":-3.709695,"eighty":-3.405847,"marketCap":624005873},{"date":"2024-09-27","current":-3.211808,"twenty":-3.980142,"median":-3.685233,"eighty":-3.395997,"marketCap":607140850},{"date":"2024-10-04","current":-2.803137,"twenty":-3.959602,"median":-3.672282,"eighty":-3.303903,"marketCap":529888161},{"date":"2024-10-11","current":-2.978693,"twenty":-3.946725,"median":-3.656453,"eighty":-3.263611,"marketCap":563074175},{"date":"2024-10-18","current":-3.462191,"twenty":-3.930629,"median":-3.608967,"eighty":-3.220442,"marketCap":654471723},{"date":"2024-10-25","current":-3.424777,"twenty":-3.915649,"median":-3.608753,"eighty":-3.22332,"marketCap":647399293},{"date":"2024-11-01","current":-3.254977,"twenty":-3.914533,"median":-3.516406,"eighty":-3.231953,"marketCap":615301345},{"date":"2024-11-08","current":-3.459313,"twenty":-3.86344,"median":-3.50536,"eighty":-3.240587,"marketCap":653927690},{"date":"2024-11-15","current":-2.016571,"twenty":-3.859807,"median":-3.465068,"eighty":-3.22332,"marketCap":481504843},{"date":"2024-11-22","current":-2.155567,"twenty":-3.851156,"median":-3.454996,"eighty":-3.18015,"marketCap":514693313},{"date":"2024-11-29","current":-2.109995,"twenty":-3.85035,"median":-3.444923,"eighty":-3.067334,"marketCap":503811848},{"date":"2024-12-06","current":-2.050751,"twenty":-3.847574,"median":-3.439167,"eighty":-2.978693,"marketCap":489665943},{"date":"2024-12-13","current":-1.911755,"twenty":-3.823752,"median":-3.419021,"eighty":-2.94646,"marketCap":456477473},{"date":"2024-12-20","current":-2.009736,"twenty":-3.802749,"median":-3.405847,"eighty":-2.329653,"marketCap":479872624},{"date":"2024-12-27","current":-1.836561,"twenty":-3.764391,"median":-3.395997,"eighty":-2.153744,"marketCap":438523055},{"date":"2025-01-03","current":-1.925427,"twenty":-3.741353,"median":-3.367218,"eighty":-2.142807,"marketCap":459741913},{"date":"2025-01-10","current":-1.595028,"twenty":-3.741353,"median":-3.312536,"eighty":-2.023407,"marketCap":380851289},{"date":"2025-01-17","current":-1.745417,"twenty":-3.740777,"median":-3.298147,"eighty":-1.989684,"marketCap":416760124},{"date":"2025-01-24","current":-1.522113,"twenty":-3.738475,"median":-3.27944,"eighty":-1.964163,"marketCap":363440944},{"date":"2025-01-31","current":-1.704402,"twenty":-3.735597,"median":-3.263611,"eighty":-1.93682,"marketCap":406966805},{"date":"2025-02-07","current":-1.291973,"twenty":-3.709695,"median":-3.247782,"eighty":-1.911755,"marketCap":308489544},{"date":"2025-02-14","current":-1.187157,"twenty":-3.703939,"median":-3.22332,"eighty":-1.873019,"marketCap":283462173},{"date":"2025-02-21","current":-1.178042,"twenty":-3.690125,"median":-3.211808,"eighty":-1.829725,"marketCap":281285880},{"date":"2025-02-28","current":-1.059555,"twenty":-3.68437,"median":-3.162882,"eighty":-1.759544,"marketCap":252994070},{"date":"2025-03-07","current":-1.111963,"twenty":-3.676887,"median":-3.070787,"eighty":-1.711693,"marketCap":265507755},{"date":"2025-03-14","current":-1.041326,"twenty":-3.672858,"median":-3.006033,"eighty":-1.678881,"marketCap":248641484},{"date":"2025-03-21","current":-0.693421,"twenty":-3.667968,"median":-2.978693,"eighty":-1.565406,"marketCap":204027476},{"date":"2025-03-28","current":-1.042906,"twenty":-3.659692,"median":-2.965742,"eighty":-1.505251,"marketCap":306857324},{"date":"2025-04-04","current":-1.85837,"twenty":-3.65559,"median":-2.803137,"eighty":-1.500694,"marketCap":546793636},{"date":"2025-04-11","current":-1.198232,"twenty":-3.63199,"median":-2.286587,"eighty":-1.463027,"marketCap":352559478},{"date":"2025-04-17","current":-0.924562,"twenty":-3.622781,"median":-2.176074,"eighty":-1.280365,"marketCap":272036635},{"date":"2025-04-25","current":-0.791425,"twenty":-3.613572,"median":-2.146452,"eighty":-1.183511,"marketCap":232863359},{"date":"2025-05-02","current":-0.848748,"twenty":-3.60871,"median":-2.125945,"eighty":-1.162092,"marketCap":249729630},{"date":"2025-05-09","current":-0.930109,"twenty":-3.590112,"median":-2.016571,"eighty":-1.140673,"marketCap":273668854},{"date":"2025-05-16","current":-0.890525,"twenty":-3.561975,"median":-1.997203,"eighty":-1.105127,"marketCap":305759157},{"date":"2025-05-23","current":-0.766929,"twenty":-3.530406,"median":-1.968721,"eighty":-1.070948,"marketCap":263322832},{"date":"2025-05-30","current":-0.619565,"twenty":-3.51429,"median":-1.964163,"eighty":-1.045883,"marketCap":212725677},{"date":"2025-06-06","current":-0.530829,"twenty":-3.506511,"median":-1.95277,"eighty":-1.037224,"marketCap":182258572},{"date":"2025-06-13","current":-0.503891,"twenty":-3.48667,"median":-1.925427,"eighty":-0.984896,"marketCap":173009629},{"date":"2025-06-20","current":-0.476954,"twenty":-3.466829,"median":-1.916313,"eighty":-0.943233,"marketCap":163760687},{"date":"2025-06-27","current":-0.522906,"twenty":-3.464493,"median":-1.909477,"eighty":-0.920124,"marketCap":179538295},{"date":"2025-07-03","current":-0.538752,"twenty":-3.462191,"median":-1.878715,"eighty":-0.88573,"marketCap":184978849},{"date":"2025-07-11","current":-0.564105,"twenty":-3.459313,"median":-1.85837,"eighty":-0.848748,"marketCap":193683736},{"date":"2025-07-18","current":-0.556182,"twenty":-3.450679,"median":-1.833144,"eighty":-0.808067,"marketCap":190963459},{"date":"2025-07-25","current":-0.611642,"twenty":-3.444923,"median":-1.819538,"eighty":-0.791425,"marketCap":210005399},{"date":"2025-08-01","current":-0.65601,"twenty":-3.444923,"median":-1.768203,"eighty":-0.766929,"marketCap":225238952},{"date":"2025-08-08","current":-1.301335,"twenty":-3.442045,"median":-1.745417,"eighty":-0.761839,"marketCap":446809517},{"date":"2025-08-15","current":-2.007939,"twenty":-3.439167,"median":-1.743138,"eighty":-0.765537,"marketCap":456842285},{"date":"2025-08-22","current":-2.103991,"twenty":-3.427655,"median":-1.761367,"eighty":-0.766929,"marketCap":478695789},{"date":"2025-08-29","current":-2.14973,"twenty":-3.424777,"median":-1.805264,"eighty":-0.766929,"marketCap":489102219},{"date":"2025-09-05","current":-2.103991,"twenty":-3.415567,"median":-1.826307,"eighty":-0.771366,"marketCap":478695789},{"date":"2025-09-12","current":-1.994217,"twenty":-3.40866,"median":-1.836561,"eighty":-0.773109,"marketCap":453720356},{"date":"2025-09-19","current":-1.9622,"twenty":-3.406179,"median":-1.867544,"eighty":-0.787793,"marketCap":446435855},{"date":"2025-09-26","current":-1.824983,"twenty":-3.405847,"median":-1.875296,"eighty":-0.795863,"marketCap":415216564},{"date":"2025-10-03","current":-1.811262,"twenty":-3.397967,"median":-1.860219,"eighty":-0.799931,"marketCap":412094635},{"date":"2025-10-10","current":-2.071974,"twenty":-3.391392,"median":-1.873019,"eighty":-0.803629,"marketCap":471411288},{"date":"2025-10-17","current":-2.108565,"twenty":-3.371823,"median":-1.884428,"eighty":-0.807327,"marketCap":479736432},{"date":"2025-10-24","current":-2.108565,"twenty":-3.341892,"median":-1.893592,"eighty":-0.812505,"marketCap":479736432},{"date":"2025-10-31","current":-2.131434,"twenty":-3.317141,"median":-1.904969,"eighty":-0.82249,"marketCap":484939647},{"date":"2025-11-07","current":-2.158878,"twenty":-3.30563,"median":-1.911755,"eighty":-0.843135,"marketCap":491183505},{"date":"2025-11-14","current":-2.422653,"twenty":-3.301601,"median":-1.918592,"eighty":-0.848547,"marketCap":551197167},{"date":"2025-11-21","current":-2.946741,"twenty":-3.29642,"median":-1.93682,"eighty":-0.86502,"marketCap":722402348},{"date":"2025-11-28","current":-3.266113,"twenty":-3.290089,"median":-1.953052,"eighty":-0.869088,"marketCap":800697401},{"date":"2025-12-05","current":-3.534386,"twenty":-3.297571,"median":-1.962042,"eighty":-0.870197,"marketCap":866465244},{"date":"2025-12-12","current":-4.943882,"twenty":-3.336738,"median":-1.966442,"eighty":-0.879813,"marketCap":1212007408},{"date":"2025-12-19","current":-4.709675,"twenty":-3.399937,"median":-1.972322,"eighty":-0.888607,"marketCap":1154591037},{"date":"2025-12-26","current":-4.854457,"twenty":-3.410963,"median":-1.990368,"eighty":-0.898223,"marketCap":1190084794},{"date":"2026-01-02","current":-4.156097,"twenty":-3.436865,"median":-1.996504,"eighty":-0.911618,"marketCap":1018879613},{"date":"2026-01-09","current":-7.741582,"twenty":-3.449528,"median":-2.003365,"eighty":-0.920124,"marketCap":1897872066},{"date":"2026-01-16","current":-12.290084,"twenty":-3.466829,"median":-2.013154,"eighty":-0.925671,"marketCap":3012950964},{"date":"2026-01-23","current":-13.362987,"twenty":-3.516406,"median":-2.019374,"eighty":-0.930109,"marketCap":3275976472},{"date":"2026-01-30","current":-13.647739,"twenty":-3.577828,"median":-2.030809,"eighty":-0.937506,"marketCap":3345784190},{"date":"2026-02-06","current":-13.393497,"twenty":-3.626234,"median":-2.053678,"eighty":-0.942816,"marketCap":3283455871},{"date":"2026-02-13","current":-13.6274,"twenty":-3.672282,"median":-2.062826,"eighty":-0.944902,"marketCap":3340797925},{"date":"2026-02-20","current":-14.850306,"twenty":-3.690125,"median":-2.071974,"eighty":-0.965612,"marketCap":3640597141},{"date":"2026-02-27","current":-15.244382,"twenty":-3.739051,"median":-2.087982,"eighty":-0.981145,"marketCap":3737206037},{"date":"2026-03-06","current":-14.054527,"twenty":-3.801818,"median":-2.103991,"eighty":-0.986058,"marketCap":3445509501},{"date":"2026-03-13","current":-12.727381,"twenty":-3.85035,"median":-2.108565,"eighty":-0.99467,"marketCap":3120155674},{"date":"2026-03-20","current":-13.002303,"twenty":-3.914756,"median":-2.117713,"eighty":-1.01599,"marketCap":3163785497},{"date":"2026-03-27","current":-13.758909,"twenty":-3.96371,"median":-2.12686,"eighty":-1.031756,"marketCap":3347886444},{"date":"2026-04-02","current":-11.882219,"twenty":-4.025273,"median":-2.141239,"eighty":-1.038592,"marketCap":2891240839},{"date":"2026-04-10","current":-11.991997,"twenty":-4.096739,"median":-2.146452,"eighty":-1.041326,"marketCap":2917952699},{"date":"2026-04-17","current":-13.068872,"twenty":-4.165061,"median":-2.15037,"eighty":-1.042274,"marketCap":3179983325},{"date":"2026-04-24","current":-13.5864,"twenty":-4.472062,"median":-2.155567,"eighty":-1.044692,"marketCap":3305910664},{"date":"2026-05-01","current":-12.906818,"twenty":-4.742038,"median":-2.161164,"eighty":-1.045883,"marketCap":3140551531},{"date":"2026-05-08","current":-12.420656,"twenty":-4.831463,"median":-2.172599,"eighty":-1.054086,"marketCap":3022256152},{"date":"2026-05-15","current":-13.226323,"twenty":-4.877452,"median":-2.191451,"eighty":-1.062289,"marketCap":3140127467},{"date":"2026-05-22","current":-11.905302,"twenty":-5.029048,"median":-2.200043,"eighty":-1.070948,"marketCap":2826497196},{"date":"2026-05-29","current":-11.491811,"twenty":-7.697296,"median":-2.214811,"eighty":-1.081885,"marketCap":2728328372},{"date":"2026-06-05","current":-10.949441,"twenty":-10.746475,"median":-2.229773,"eighty":-1.094189,"marketCap":2599561472},{"date":"2026-06-12","current":-11.223311,"twenty":-10.767935,"median":-2.309816,"eighty":-1.101025,"marketCap":2664582382},{"date":"2026-06-18","current":-12.377862,"twenty":-10.942997,"median":-2.358363,"eighty":-1.105127,"marketCap":2938690139},{"date":"2026-06-26","current":-13.441123,"twenty":-11.434889,"median":-2.409687,"eighty":-1.106494,"marketCap":3191124259},{"date":"2026-07-02","current":-14.305694,"twenty":-11.51629,"median":-2.443671,"eighty":-1.111963,"marketCap":3396386347},{"date":"2026-07-10","current":-16.271116,"twenty":-11.77244,"median":-2.7977,"eighty":-1.135362,"marketCap":3863006994},{"date":"2026-07-17","current":-14.622524,"twenty":-11.882219,"median":-2.91667,"eighty":-1.139306,"marketCap":3471606615},{"date":"2026-07-24","current":-15.197115,"twenty":-11.985852,"median":-2.970059,"eighty":-1.141585,"marketCap":3608023034},{"date":"2026-07-31","current":-15.546165,"twenty":-12.051591,"median":-2.978693,"eighty":-1.145231,"marketCap":3690892821},{"date":"2026-08-07","current":-14.928615,"twenty":-12.229666,"median":-3.006033,"eighty":-1.151611,"marketCap":3544277044},{"date":"2026-08-14","current":-13.30798,"twenty":-12.354486,"median":-3.070787,"eighty":-1.160269,"marketCap":3159514183},{"date":"2026-08-21","current":-6.740728,"twenty":-12.30227,"median":-3.108556,"eighty":-1.162092,"marketCap":2958889563}],"updateTime":1787496832108},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALMS\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2623170443","title":"Alumis Inc. : Oppenheimer Raises Target Price to $55 From $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2623170443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623170443?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:24","pubTimestamp":1774873458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nAZN4SO1PL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312092","title":"Alumis price target raised to $55 from $50 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312092?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:51","pubTimestamp":1774871486,"startTime":"0","endTime":"0","summary":"Oppenheimer raised the firm’s price target on Alumis to $55 from $50 and keeps an Outperform rating on the shares. The firm sees the three new oral...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-55-from-50-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-55-from-50-at-oppenheimer-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OPY","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623782319","title":"Alumis Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623782319","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623782319?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:49","pubTimestamp":1774867740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 06:49 ET (10:49 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623319144","title":"Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2623319144","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623319144?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:35","pubTimestamp":1774866932,"startTime":"0","endTime":"0","summary":"In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on Alumis Inc., with a price target of $38.00. Terence Flynn ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alumis-inc-alms-buy-rating-on-envus-strong-phase-3-data-and-attractive-risk‑reward-ahead-of-2026-fda-submission-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alumis-inc-alms-buy-rating-on-envus-strong-phase-3-data-and-attractive-risk‑reward-ahead-of-2026-fda-submission-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623316344","title":"Alumis envudeucitinib hits 68% PASI 90 at Week 24 in Phase 3 psoriasis trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2623316344","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623316344?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:10","pubTimestamp":1774865432,"startTime":"0","endTime":"0","summary":"Alumis disclosed new Phase 3 ONWARD1 and ONWARD2 data showing envudeucitinib, an oral TYK2 inhibitor, delivered high levels of skin clearance in moderate-to-severe plaque psoriasis.Results were presented as a late-breaking oral session at 2026 American Academy of Dermatology Annual Meeting.PASI 90 reached 59.9% and 53.1% at Week 16, rising to 68% and 62.1% at Week 24.PASI 100 was 29.4% and 27.7% at Week 16, increasing to 41% and 39.5% at Week 24.Alumis plans to submit a U.S. New Drug Application in second half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Sec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLccxddQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623439425","title":"U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2623439425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623439425?lang=en_us&edition=fundamental","pubTime":"2026-03-30 15:35","pubTimestamp":1774856155,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP MorganMarch 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed comp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL4N40I0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOKF","CBSH","CCI","COIN","COIW","EOG","GM","MMM","CHWY","CONI","ETR","DVN","APGE","DOW","BKU","BALY","DASH","HIG","DH","CEGX","COYY","OZK","CTRA","FDMT","FANG","CONL","CDNL","FBP","FIGR","COLB","EYPT","FITB","DAN","DASX","CEG","FERG","ASB","COIA","BANC","BSX","FHB","ICOI","FIAT","CLMT","COII","AMT","CRC","CCL","ALMS","APA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623351411","title":"Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2623351411","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623351411?lang=en_us&edition=fundamental","pubTime":"2026-03-29 22:30","pubTimestamp":1774794606,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) announced new data from its Phase 3 Onward1 and Onward2 clinical trials evaluating envudeucitinib, a next-generation, highly selectiv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-announces-data-from-phase-3-onward1-onward23-trials-of-envudeucitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-announces-data-from-phase-3-onward1-onward23-trials-of-envudeucitinib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623872173","title":"Alumis says Phase 3 trials show envudeucitinib boosts psoriasis skin clearance by Week 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2623872173","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623872173?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719015,"startTime":"0","endTime":"0","summary":"Alumis reported Phase 3 ONWARD1 and ONWARD2 results for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis.Data were already presented as a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting.Week 24 PASI 90 reached 68.0% in ONWARD1, 62.1% in ONWARD2, up from 59.9% and 53.1% at Week 16.Complete clearance  rose to 41.0% and 39.5% at Week 24, up from 29.4% and 27.7% at Week 16.Alumis targets a US FDA New Drug Application submission in second half of 2026, positioning envudeucitinib as a potential leading oral option in plaque psoriasis.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL1Hr964:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","ALMS","LU2210149790.SGD","BK4007","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623738740","title":"Alumis: New Data From Its Phase 3 Onward1 & Onward2 Clinical Trials Evaluating Envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2623738740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623738740?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nP8N3W10B9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623402387","title":"Alumis: Envudeucitinib Showed Favorable Safety & Tolerability Profile Consistent With Phase 2 Program, No New Safety Signals Observed","url":"https://stock-news.laohu8.com/highlight/detail?id=2623402387","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623402387?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nP8N3W10B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387400","title":"Alumis: Envudeucitinib Showed Robust Skin‑Clearance, Achieving High Thresholds of Clinical Responses From Week 16 to Week 24 in Both Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387400?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nP8N3W10B9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387288","title":"Alumis: Continues to Evaluate Long-Term Efficacy & Safety of Envudeucitinib in Onward3 Long-Term Extension Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387288","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623387288?lang=en_us&edition=fundamental","pubTime":"2026-03-29 01:30","pubTimestamp":1774719000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nP8N3W10B9:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621371719","title":"The Bull Case For Alumis (ALMS) Could Change Following Envudeucitinib Phase 3 Data And New Equity Plans - Learn Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2621371719","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621371719?lang=en_us&edition=fundamental","pubTime":"2026-03-22 13:08","pubTimestamp":1774156138,"startTime":"0","endTime":"0","summary":"Alumis reported full-year 2025 results showing US$24.05 million in revenue and a net loss of US$243.33 million, while also filing a universal shelf registration and a US$300 million at-the-market follow-on equity offering alongside positive Phase 3 topline data for its TYK2 inhibitor envudeucitinib in plaque psoriasis.\nBy pairing encouraging late-stage clinical data and plans for a 2026 New Drug Application with expanded financing flexibility, Alumis is signaling a push to advance...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/the-bull-case-for-alumis-alms-could-change-following-envudeu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/the-bull-case-for-alumis-alms-could-change-following-envudeu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["EQR","BK4585","ALMS","BK4588","BK4215","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621750387","title":"Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2621750387","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621750387?lang=en_us&edition=fundamental","pubTime":"2026-03-21 07:14","pubTimestamp":1774048492,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has just wrapped up FY 2025 with Q4 revenue of US$1.9 million, a basic EPS loss of US$0.89 per share, and a net loss of US$92.9 million. On a trailing twelve month basis, revenue was US$24.1 million, with a basic EPS loss of US$2.86 per share and a net loss of US$243.3 million. Over recent quarters, revenue moved from US$17.4 million in Q1 2025 to US$2.7 million in Q2, US$2.1 million in Q3, and US$1.9 million in Q4. EPS shifted from a loss of US$1.82 in Q1 to a profit of US$0.78...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/alumis-alms-q4-loss-of-us929-million-tests-bullish-growth-na","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-alms/alumis/news/alumis-alms-q4-loss-of-us929-million-tests-bullish-growth-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BLSX","BK4112","BLSG","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620731878","title":"Alumis Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731878?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:28","pubTimestamp":1774013280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 09:28 ET (13:28 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620873546","title":"Alumis Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620873546","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620873546?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:24","pubTimestamp":1774009440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 08:24 ET (12:24 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620803677","title":"Alumis price target raised to $38 from $33 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620803677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620803677?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:51","pubTimestamp":1774003860,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Terence Flynn raised the firm’s price target on Alumis (ALMS) to $38 from $33 and keeps an Overweight rating on the shares. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-38-from-33-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-price-target-raised-to-38-from-33-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620782840?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:00","pubTimestamp":1774000800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEF","JBS","FENC","KOD","KALV","BTGO","KBH","EPAC","CELC","ABSI","EQ","CNTA","HSAI","DERM","FUFU","BZAI","FBRX","CGNT","CNTX","GOVX","CNM","IKT","IMNN","CUK","CNXC","FEMY","FUL","BRZE","CHWY","CNTB","AIR","EDAP","BAK","KRMN","ALMS","AVTX","AGX","MXCT","DOO","BYND","EVTL","ABVX","CTAS","GUTS","HYPD","HUMA","BCAX","ACHV","CMC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620720029","title":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedEx","url":"https://stock-news.laohu8.com/highlight/detail?id=2620720029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620720029?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:50","pubTimestamp":1773989443,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedExMarch 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Products,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL4N4080E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHX","XOMX","APA","FANG","AR","CAKE","CVX","CRGY","AEIS","FIVE","ALMS","FLNC","GAP","FIGS","CDNL","CQP","ALL","EOG","FDX","LU2211815571.USD","BRZE","EXE","CRC","FCFS","XOM","BSX","COHR","DRI","DRIO","APD","TGT","LU0211327993.USD","CCK","CEVA","COP","EL","GNLX","CAG","ETON","LU0154236417.USD","ATR","CMG","XOMZ","LU2357305700.SGD","XOMO","CMGG","CNX","AMH","LNG","FRPT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620714082","title":"Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620714082","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620714082?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:16","pubTimestamp":1773954960,"startTime":"0","endTime":"0","summary":"Alumis plans to seek Food and Drug Administration approval in the later this year for its lead drug candidate after reporting positive late-stage trial results.The disclosure comes as the biotechnology company on Thursday said it narrowed its loss last year and strengthened its balance sheet with a recent equity raise.Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete skin clearance and more than 40% achieved complete clearance at 24 weeks, with a safety profile consistent with earlier studies.The company said it intends to submit a new-drug application to the FDA in the second half of this year, and that it will present additional data from the trials later this month at a dermatology conference.Alumis is also studying the drug in systemic lupus erythematosus, with midstage data expected in the third quarter.Separately, the company said it","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4585","BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":98,"code":"91000000","status":"200"}]}}